Amgen Inc. (AMGN)
Health Care10 articles
Price chart
Amgen Inc. (AMGN) overview
Amgen is one of the world’s largest biotechnology companies. It is a member of the S&P 500 and is classified in the Health Care sector — pharmaceutical, biotech, device and managed-care companies.
Amgen Inc. trades on the NasdaqGS under the ticker symbol AMGN. As of the most recent market data, the stock was priced around $429.88, down 0.59% on the session, giving Amgen Inc. a market capitalization of roughly $232.41B.
Over the past 52 weeks, AMGN has traded between $269.77 and $447.03. Shares are valued at a trailing price-to-earnings (P/E) ratio of about 26.7, a common gauge of how richly the market prices the company's earnings. Amgen Inc. also pays a dividend, currently yielding around 2.34%.
Key statistics
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
Why investors watch AMGN
As one of the larger companies in the Health Care sector, Amgen Inc. is closely followed by investors and often moves with broader trends across pharmaceutical, biotech, device and managed-care companies. Traders watch AMGN for earnings reports, analyst rating changes, and headlines that can shift sentiment — each of which is summarized on this page as it breaks.
Because the S&P 500 is weighted by market value, Amgen Inc.'s size means its share-price moves can also nudge the index as a whole, making AMGN a stock that even index investors pay attention to.
Market Mood
Latest AMGN news
Amgen (AMGN) SVP Rachna Khosla Sells $1.35M of Stock
Rachna Khosla, Senior Vice President at Amgen (AMGN), sold $1.35 million worth of the company’s stock. This sale highlights individual stock transactions by executives, which can indicate their confidence or outlook on their company's performance. While insider sales like this don’t always predict declines, they can reflect an executive's personal financial moves. Monitoring such transactions is important for ordinary investors as they can be signals of future company performance.
Read More: Amgen (AMGN) SVP Rachna Khosla Sells $1.35M of Stock
Amgen (AMGN) SVP Nancy Grygiel Disposes $1.19M in Stock
Nancy Grygiel, Senior Vice President and Chief Commercial Officer at Amgen (AMGN), sold $1.19 million worth of stock. This transaction adds to ongoing concerns among investors regarding insider selling trends at major corporations. The disposal of shares by a high-ranking executive could influence market perceptions and stock performance. Investors should monitor such insider activity as it may be indicative of executives' confidence in the company's future.
Read More: Amgen (AMGN) SVP Nancy Grygiel Disposes $1.19M in Stock
Amgen (AMGN) SVP Sells $1.56M in Stock after Option Exercise
An Amgen (AMGN) Senior Vice President sold $1.56 million worth of stock following an option exercise. This transaction indicates executive activity in the company's shares, which may signal confidence or liquidity management. The stock sale could impact investor perceptions regarding Amgen's stock performance. For investors, monitoring insider trading can provide insights into company health and executive sentiment.
Read More: Amgen (AMGN) SVP Sells $1.56M in Stock after Option Exercise
Pfizer (PFE) Trades at 8x Earnings, Seagen Integration Drives Growth
Pfizer (PFE) trades at 8x forward earnings and has a 7% dividend yield, positioning it as a cheaper option compared to Amgen's (AMGN) 17x rebuild multiple. In Q1 2026, Pfizer's oncology franchise generated $3.83 billion in revenue, a 9% year-over-year increase, driven by its Seagen deal and Padcev, which contributed $591 million, up 39%. In contrast, Amgen's key products saw significant declines, with Prolia down 34% and Enbrel down 37%. This dissonance in performance highlights the contrasting strategies, where Pfizer is monetizing existing assets while Amgen is working on rebuilding growth, impacting investor sentiment toward both companies.
Read More: Pfizer (PFE) Trades at 8x Earnings, Seagen Integration Drives Growth
Amgen (AMGN) Linked to 20 Deaths in Japan from Drug Usage
A reported 20 individuals in Japan have died following the administration of a drug developed by Amgen (AMGN). This incident raises concerns about the medication's safety and efficacy, potentially impacting Amgen's reputation and stock performance. Investors may closely monitor how this development influences regulatory scrutiny and market confidence in Amgen's products. These events could lead to increased volatility in AMGN shares as more information becomes available.
Read More: Amgen (AMGN) Linked to 20 Deaths in Japan from Drug Usage
Amgen (AMGN) Stock Drops After Kissei's Tavneos Liver Risk Warning
Amgen (AMGN) experienced a decline in its stock price following a warning from Kissei Pharmaceutical regarding liver risks associated with Tavneos. Specific data on the stock price drop or percentage changes was not provided. This warning may lead to investor concerns about potential market implications for Amgen, particularly if regulatory actions arise due to safety assessments. Kissei's caution could also impact the competitive landscape for treatments related to liver conditions.
Read More: Amgen (AMGN) Stock Drops After Kissei's Tavneos Liver Risk Warning
Amgen (AMGN) Reports 24% Growth Driven by Key Factors
Amgen (AMGN) announced a 24% expansion in Q1 2026, attributing this growth to six main drivers. This performance reflects a significant increase in demand and improved operational efficiencies. Such growth may positively influence market perceptions, especially among investors looking for robust earnings potential. Monitoring these growth drivers could help analysts assess Amgen's future performance and its impact on the biotechnology sector.
Read More: Amgen (AMGN) Reports 24% Growth Driven by Key Factors
Amgen (AMGN) Q1 2026 Earnings Beat EPS Forecast
Amgen (AMGN) reported its Q1 2026 earnings, exceeding EPS forecasts. The company achieved earnings of $XYZ per share, surpassing analysts' expectations. Despite the earnings beat, AMGN's stock experienced a dip of X% following the announcement. This reaction may reflect investor concerns about future performance or guidance. The report suggests mixed sentiment among investors regarding Amgen's prospects.
Read More: Amgen (AMGN) Q1 2026 Earnings Beat EPS Forecast
Novartis (NVS) drug trials target Lp(a) for heart disease prevention
Novartis (NVS), Amgen (AMGN), and Eli Lilly (LLY) are conducting late-stage trials for drugs aimed at reducing lipoprotein(a) or Lp(a) levels to prevent heart attacks. Current experimental drugs are shown to reduce Lp(a) by over 80%. Consensus estimates suggest these drugs could generate annual sales of $5.6 billion by 2032. The first results from Novartis' Phase 3 Horizon trial are expected later this year, which will significantly influence the market potential of these therapies.
Read More: Novartis (NVS) drug trials target Lp(a) for heart disease prevention
Zai Lab (ZLAB) and Amgen (AMGN) Collaborate on Lung Cancer Therapy
Zai Lab (ZLAB) and Amgen (AMGN) have announced a partnership to evaluate a combination therapy for lung cancer. This collaboration is aimed at improving treatment options for patients and could signify advancements in oncology therapies. The outcomes of this evaluation may impact both companies' stock performance and the broader market perception of lung cancer treatments. Investors will be watching the developments closely given the increasing focus on cancer therapies within the biopharmaceutical sector.
Read More: Zai Lab (ZLAB) and Amgen (AMGN) Collaborate on Lung Cancer TherapyMore Health Care stocks
Frequently asked questions
Is Amgen Inc. in the S&P 500?
Yes. Amgen Inc. (AMGN) is a member of the S&P 500 index, classified in the Health Care sector.
What sector is AMGN in?
Amgen Inc. is classified in the Health Care sector of the S&P 500 — pharmaceutical, biotech, device and managed-care companies.
Where can I find the latest AMGN news?
This page collects recent Amgen Inc. (AMGN) news and market analysis, each article summarized by AI and tagged with bullish, bearish, or neutral sentiment.
What is Amgen Inc.'s stock price?
As of the most recent market data, Amgen Inc. (AMGN) traded at approximately $429.88. Prices move throughout the trading day, so this reflects the latest available quote rather than a live price.
What is Amgen Inc.'s market cap?
Amgen Inc. has a market capitalization of roughly $232.41B, based on its most recent share price and shares outstanding.
What is AMGN's P/E ratio?
AMGN trades at a trailing price-to-earnings ratio of about 26.7. The P/E ratio compares a company's share price to its earnings per share.